Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This French trial looks new. Inhaled IFN Beta 1b - couldn't be much closer!
It's open label though, and they haven't even started recruiting yet.
https://www.clinicaltrials.gov/ct2/show/NCT04469491
Well spotted SGD27,
Have been following the tweets from that French doctor for a while , giving out about the delays in getting approval to do this trial ...
Will keep an eye open :-)
I'm just wondering about the patent situation. This one seems to cover 1a & 1b :
https://patents.justia.com/patent/9421243
Good question SGD27,
It seems that it's the Amiens hospital that is sponsoring this clinical trial and not a biotech company ...it would be surprising if they did'nt do the research on the patent situation before going ahead ...
Don't know if they are breaching the SNG patent or not ...
Synairgen are covered for both 1a and 1b, so I would be surprised if they have not infringed. Might be worth if someone who is in touch with Synairgen to flag this one up in case it isn't on their radar.
It does look as if they are.....
The French couldn't be that stupid.....could they?
I suspect we will find the trial is in collaboration with Synairgen.....?
The doctor in that study is certainly aware of Synairgen:
https://i.postimg.cc/YCMw5VKp/aurelien.png
I'd give RM a ring if I thought it was something significant that needed clearing up (don't mean to sound flippant).
IR won't know anything (they're generally just like your marketing department and will point you to existing information). However I'm confident I know what his answer would be, in that they feel their IP is well protected, and that they're either aware or not bothered. In fact the increasing body of evidence supporting IFN-B usage (inhaled or not) is really only a good thing for SNG.
Of course if someone was trying to sell or distribute inhaled IFN-B....I imagine they might be on the phone to the lawyers ;)
Let them do the research and trial, then swoop in just after the results. :o.
Rich ,
Interferons are natural products and therefore are not as such patentable ....
Sng have a patent for a method of usage or specific formulation of inf beta 1a & 1b that is covered by their patent so that cannot be copied but
Others have a different formula etc
Yes I know that. They have a patent on the inhalation method for treating not interferons as a whole obviously.
@ChrisToffer : Yes, and that makes it a bit hard to understand what exactly is motivating them to start this new trial now. (If it was in some sort of collaboration with SNG we'd surely have been informed in an RNS by now.)
They've seen what's likely to work and fancy some research money to pay the bills for another few months? :p
How far along the trials route is TILS? If it's a Ferrari it must have a puncture.:)
SGD, or may be because theyve identified a huge market for this type of drug?
They would still have to go through the trial amd approval process but they may see value in doing so, even if it takes a few years.
Miggy ,
I keep telling you that TILS is not a covid stock ...but whatever
The market has upgraded them to formula 1 status :-)
ChrisToffer....that SNG have the patent on....
Sgd27,
They are doctors and scientists, they want to follow the science so they want to test ..
True they have a few things going on but their Covid drug, is only about to start toxicology and safety tests, months and months behind. Well behind SNG on the trials front yet their market cap is around £250m. Thats what is annoying about the current SP here. SNG isn't justa COVID play either there attention switched to this in January when the virus came to our attention. COPD is a huge market in its own right.:)
In my opinion they won't be using our ´formulation ´ of interferon but their own
So no patent problem that I can see , and don't forget that it's the French health minister who is technically behind this :-)
I better not answer you about tils because Sharestring will be on to his MP again :-)
Anyway if you take the time to do the research you will see why they are at that MArket Cap
Thanks Rich, I was under the impression that there would be nothing stopping another company making a formulation of interferon and running trials to get approvals on that formulation.
Having read that link to the patent below it kind of reads like its INF in general, but particularly administered via inhalation. Have to admit it's not something I have any experience in though.
I don't think it'd be as simple as just varying the formulation Chris otherwise AZN wouldn't have committed to the hundreds of millions when they were going for the Asthma indication. They'd just have done that themselves. Therefore I'm pretty comfortable the patent is good enough for its purpose (i.e. inhalation of IFN-B).
Fair enough! I just had a look over the annual report that highlights some risks around protecting the IP and that it may involve litigation at a cost . You'd like to think that the patent would be well protected in Europe at least.
Regardless on the patent, there's a race on for countries preparing for the winter flu season and SNG are well positioned to contribute to that. Just need those results to be positive!